| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endovascular Procedures | 44 | 2026 | 631 | 7.480 |
Why?
|
| Blood Vessel Prosthesis Implantation | 29 | 2026 | 277 | 6.140 |
Why?
|
| Peripheral Arterial Disease | 21 | 2025 | 165 | 5.840 |
Why?
|
| Aortic Aneurysm, Abdominal | 26 | 2026 | 228 | 5.780 |
Why?
|
| Vascular Surgical Procedures | 28 | 2025 | 240 | 5.270 |
Why?
|
| Intermittent Claudication | 11 | 2025 | 53 | 3.980 |
Why?
|
| Blood Vessel Prosthesis | 20 | 2026 | 215 | 3.080 |
Why?
|
| Lower Extremity | 11 | 2024 | 160 | 2.700 |
Why?
|
| Treatment Outcome | 67 | 2026 | 5806 | 2.090 |
Why?
|
| Ischemia | 9 | 2022 | 203 | 1.960 |
Why?
|
| Risk Factors | 53 | 2026 | 5458 | 1.920 |
Why?
|
| Time Factors | 51 | 2026 | 3774 | 1.800 |
Why?
|
| Retrospective Studies | 63 | 2026 | 6929 | 1.770 |
Why?
|
| Postoperative Complications | 22 | 2026 | 1334 | 1.580 |
Why?
|
| Risk Assessment | 33 | 2026 | 2111 | 1.530 |
Why?
|
| Quality Indicators, Health Care | 10 | 2026 | 348 | 1.510 |
Why?
|
| Aortic Aneurysm | 4 | 2021 | 81 | 1.470 |
Why?
|
| Endoleak | 6 | 2026 | 39 | 1.440 |
Why?
|
| Stents | 11 | 2025 | 500 | 1.410 |
Why?
|
| General Surgery | 3 | 2025 | 210 | 1.340 |
Why?
|
| Exercise Therapy | 4 | 2025 | 102 | 1.250 |
Why?
|
| Hospital Mortality | 17 | 2025 | 879 | 1.230 |
Why?
|
| Aortic Aneurysm, Thoracic | 5 | 2022 | 109 | 1.210 |
Why?
|
| Aged | 67 | 2026 | 15052 | 1.200 |
Why?
|
| Aged, 80 and over | 39 | 2026 | 5644 | 1.200 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2025 | 708 | 1.160 |
Why?
|
| Humans | 115 | 2026 | 65463 | 1.140 |
Why?
|
| Male | 78 | 2026 | 31187 | 1.080 |
Why?
|
| Limb Salvage | 6 | 2022 | 65 | 1.040 |
Why?
|
| Female | 79 | 2026 | 34193 | 1.030 |
Why?
|
| Databases, Factual | 21 | 2026 | 887 | 1.010 |
Why?
|
| Endarterectomy, Carotid | 7 | 2024 | 79 | 1.000 |
Why?
|
| Quality Improvement | 6 | 2025 | 468 | 0.990 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2021 | 46 | 0.980 |
Why?
|
| Consensus | 2 | 2025 | 177 | 0.950 |
Why?
|
| Vascular Patency | 9 | 2024 | 135 | 0.940 |
Why?
|
| Clinical Decision-Making | 3 | 2023 | 168 | 0.900 |
Why?
|
| Pancreatic Neoplasms | 8 | 2010 | 354 | 0.840 |
Why?
|
| Middle Aged | 49 | 2025 | 18387 | 0.830 |
Why?
|
| Cultural Diversity | 1 | 2025 | 54 | 0.830 |
Why?
|
| Registries | 18 | 2025 | 929 | 0.820 |
Why?
|
| Prosthesis Design | 14 | 2026 | 221 | 0.810 |
Why?
|
| Fibrinolytic Agents | 1 | 2025 | 181 | 0.800 |
Why?
|
| Career Choice | 1 | 2025 | 127 | 0.790 |
Why?
|
| Minority Groups | 1 | 2025 | 142 | 0.790 |
Why?
|
| Benchmarking | 5 | 2025 | 137 | 0.780 |
Why?
|
| Practice Guidelines as Topic | 6 | 2025 | 741 | 0.770 |
Why?
|
| Iliac Aneurysm | 1 | 2023 | 10 | 0.770 |
Why?
|
| Myocardial Ischemia | 2 | 2014 | 121 | 0.760 |
Why?
|
| Vascular Grafting | 4 | 2018 | 37 | 0.750 |
Why?
|
| United States | 38 | 2026 | 8148 | 0.750 |
Why?
|
| Carotid Stenosis | 4 | 2021 | 100 | 0.750 |
Why?
|
| Liver Neoplasms | 3 | 2010 | 308 | 0.740 |
Why?
|
| Patient Readmission | 3 | 2024 | 452 | 0.740 |
Why?
|
| Surgeons | 7 | 2021 | 191 | 0.730 |
Why?
|
| Decision Support Techniques | 3 | 2025 | 194 | 0.730 |
Why?
|
| Aorta, Abdominal | 2 | 2022 | 56 | 0.710 |
Why?
|
| Walking | 2 | 2023 | 246 | 0.700 |
Why?
|
| Patient Discharge | 3 | 2024 | 521 | 0.690 |
Why?
|
| Hepatectomy | 4 | 2010 | 63 | 0.690 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2021 | 419 | 0.680 |
Why?
|
| Reimbursement, Incentive | 2 | 2019 | 29 | 0.680 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 92 | 0.640 |
Why?
|
| Spinal Cord Ischemia | 1 | 2020 | 15 | 0.630 |
Why?
|
| Hospitals, High-Volume | 4 | 2026 | 36 | 0.620 |
Why?
|
| Celiac Artery | 1 | 2019 | 13 | 0.600 |
Why?
|
| Pancreatectomy | 6 | 2010 | 99 | 0.600 |
Why?
|
| Drainage | 1 | 2020 | 153 | 0.590 |
Why?
|
| Guideline Adherence | 4 | 2026 | 310 | 0.590 |
Why?
|
| Baths | 1 | 2019 | 7 | 0.580 |
Why?
|
| Hygiene | 1 | 2019 | 13 | 0.580 |
Why?
|
| Patient Care Bundles | 1 | 2019 | 11 | 0.580 |
Why?
|
| Chlorhexidine | 1 | 2019 | 17 | 0.580 |
Why?
|
| Intraoperative Care | 1 | 2019 | 38 | 0.580 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2019 | 29 | 0.570 |
Why?
|
| Physician Incentive Plans | 1 | 2018 | 9 | 0.570 |
Why?
|
| Internship and Residency | 3 | 2021 | 803 | 0.550 |
Why?
|
| Economics, Hospital | 1 | 2017 | 15 | 0.540 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 126 | 0.530 |
Why?
|
| Health Expenditures | 2 | 2017 | 122 | 0.510 |
Why?
|
| Patient Selection | 6 | 2023 | 484 | 0.510 |
Why?
|
| Device Approval | 1 | 2017 | 13 | 0.510 |
Why?
|
| Reoperation | 7 | 2026 | 307 | 0.500 |
Why?
|
| Survival Rate | 10 | 2021 | 847 | 0.500 |
Why?
|
| Inpatients | 2 | 2019 | 322 | 0.480 |
Why?
|
| Computed Tomography Angiography | 5 | 2021 | 141 | 0.480 |
Why?
|
| Comorbidity | 14 | 2024 | 1120 | 0.470 |
Why?
|
| Medicare | 6 | 2022 | 627 | 0.450 |
Why?
|
| Aortic Diseases | 3 | 2023 | 65 | 0.420 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2020 | 44 | 0.420 |
Why?
|
| Quality of Health Care | 1 | 2018 | 533 | 0.410 |
Why?
|
| Models, Biological | 1 | 2019 | 1192 | 0.410 |
Why?
|
| Natural Language Processing | 2 | 2026 | 57 | 0.410 |
Why?
|
| Fee-for-Service Plans | 3 | 2020 | 71 | 0.400 |
Why?
|
| Aortic Rupture | 4 | 2026 | 47 | 0.390 |
Why?
|
| Quality of Life | 4 | 2025 | 1263 | 0.390 |
Why?
|
| Education, Medical, Graduate | 4 | 2021 | 348 | 0.370 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2025 | 159 | 0.370 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 921 | 0.350 |
Why?
|
| Hospitals, Low-Volume | 2 | 2025 | 20 | 0.350 |
Why?
|
| Chi-Square Distribution | 10 | 2016 | 413 | 0.340 |
Why?
|
| Ultrasonography, Doppler, Duplex | 3 | 2021 | 48 | 0.340 |
Why?
|
| Predictive Value of Tests | 8 | 2026 | 1114 | 0.330 |
Why?
|
| Needs Assessment | 2 | 2025 | 202 | 0.320 |
Why?
|
| Prospective Studies | 8 | 2023 | 3324 | 0.320 |
Why?
|
| Aortography | 6 | 2022 | 58 | 0.310 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 142 | 0.300 |
Why?
|
| Digestive System Diseases | 1 | 2009 | 14 | 0.300 |
Why?
|
| Elective Surgical Procedures | 4 | 2025 | 120 | 0.300 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 37 | 0.300 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 31 | 0.300 |
Why?
|
| Medicare Access and CHIP Reauthorization Act of 2015 | 2 | 2019 | 2 | 0.290 |
Why?
|
| New England | 4 | 2016 | 271 | 0.290 |
Why?
|
| Relative Value Scales | 2 | 2020 | 14 | 0.280 |
Why?
|
| Clinical Coding | 3 | 2018 | 46 | 0.270 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 175 | 0.270 |
Why?
|
| Chronic Disease | 3 | 2020 | 742 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2025 | 1021 | 0.250 |
Why?
|
| Amyloid | 2 | 2025 | 74 | 0.250 |
Why?
|
| Physician's Role | 2 | 2018 | 122 | 0.240 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2492 | 0.240 |
Why?
|
| Societies, Medical | 3 | 2025 | 400 | 0.230 |
Why?
|
| Renal Dialysis | 2 | 2018 | 191 | 0.230 |
Why?
|
| Stroke | 3 | 2021 | 1213 | 0.230 |
Why?
|
| Massachusetts | 7 | 2020 | 2153 | 0.230 |
Why?
|
| Computer Simulation | 2 | 2019 | 485 | 0.230 |
Why?
|
| Clinical Competence | 3 | 2021 | 732 | 0.230 |
Why?
|
| SEER Program | 6 | 2010 | 75 | 0.230 |
Why?
|
| Logistic Models | 11 | 2016 | 1273 | 0.230 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 1710 | 0.220 |
Why?
|
| Pneumococcal Infections | 1 | 2025 | 39 | 0.220 |
Why?
|
| Evidence-Based Medicine | 2 | 2025 | 464 | 0.220 |
Why?
|
| Streptococcus pneumoniae | 1 | 2025 | 67 | 0.220 |
Why?
|
| Phosphorylcholine | 1 | 2025 | 45 | 0.220 |
Why?
|
| Mobility Limitation | 1 | 2025 | 49 | 0.220 |
Why?
|
| C-Reactive Protein | 1 | 2025 | 169 | 0.210 |
Why?
|
| Aneurysm, Infected | 2 | 2015 | 13 | 0.210 |
Why?
|
| Patient Compliance | 2 | 2019 | 370 | 0.210 |
Why?
|
| Hospitals | 5 | 2010 | 397 | 0.210 |
Why?
|
| Patient Preference | 1 | 2024 | 86 | 0.200 |
Why?
|
| Health Services Misuse | 1 | 2023 | 21 | 0.200 |
Why?
|
| Workload | 2 | 2021 | 132 | 0.200 |
Why?
|
| Unnecessary Procedures | 1 | 2023 | 50 | 0.200 |
Why?
|
| Hospital Costs | 4 | 2020 | 126 | 0.190 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2021 | 60 | 0.190 |
Why?
|
| Aneurysm, False | 1 | 2023 | 47 | 0.190 |
Why?
|
| Software | 1 | 2026 | 401 | 0.190 |
Why?
|
| Odds Ratio | 7 | 2016 | 755 | 0.180 |
Why?
|
| Electronic Health Records | 1 | 2026 | 394 | 0.180 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 367 | 0.180 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 235 | 0.180 |
Why?
|
| Length of Stay | 7 | 2020 | 828 | 0.180 |
Why?
|
| Retreatment | 2 | 2019 | 43 | 0.180 |
Why?
|
| Mutation, Missense | 2 | 2020 | 190 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 59 | 0.180 |
Why?
|
| Insulins | 1 | 2022 | 15 | 0.180 |
Why?
|
| Fiber Optic Technology | 1 | 2021 | 22 | 0.180 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 244 | 0.180 |
Why?
|
| Leadership | 3 | 2021 | 212 | 0.170 |
Why?
|
| Sex Characteristics | 1 | 2023 | 213 | 0.170 |
Why?
|
| Aorta | 2 | 2023 | 108 | 0.170 |
Why?
|
| Physicians | 2 | 2022 | 482 | 0.170 |
Why?
|
| Sexism | 1 | 2021 | 31 | 0.170 |
Why?
|
| Prognosis | 4 | 2021 | 1789 | 0.170 |
Why?
|
| Physicians, Women | 1 | 2021 | 43 | 0.170 |
Why?
|
| Iliac Artery | 1 | 2021 | 43 | 0.170 |
Why?
|
| Renal Artery | 1 | 2021 | 36 | 0.170 |
Why?
|
| Reimbursement Mechanisms | 2 | 2018 | 41 | 0.160 |
Why?
|
| Health Facilities | 1 | 2020 | 46 | 0.160 |
Why?
|
| Angioplasty, Balloon | 1 | 2020 | 55 | 0.160 |
Why?
|
| Cutis Laxa | 1 | 2020 | 8 | 0.160 |
Why?
|
| Intraoperative Complications | 1 | 2021 | 88 | 0.160 |
Why?
|
| Current Procedural Terminology | 2 | 2020 | 18 | 0.160 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 49 | 0.160 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 111 | 0.160 |
Why?
|
| Post-Dural Puncture Headache | 1 | 2020 | 5 | 0.160 |
Why?
|
| Equipment and Supplies | 1 | 2020 | 19 | 0.160 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2020 | 10 | 0.160 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2020 | 8 | 0.160 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2020 | 36 | 0.160 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 1564 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 46 | 0.160 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 26 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 460 | 0.160 |
Why?
|
| Incidence | 3 | 2018 | 1430 | 0.160 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2020 | 17 | 0.160 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 744 | 0.160 |
Why?
|
| Documentation | 2 | 2018 | 135 | 0.150 |
Why?
|
| Data Accuracy | 2 | 2018 | 31 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2024 | 529 | 0.150 |
Why?
|
| Patient Care Team | 3 | 2020 | 336 | 0.150 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2010 | 49 | 0.150 |
Why?
|
| Saphenous Vein | 1 | 2019 | 51 | 0.150 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2020 | 110 | 0.140 |
Why?
|
| Atherectomy | 1 | 2018 | 8 | 0.140 |
Why?
|
| Upper Extremity | 1 | 2018 | 57 | 0.140 |
Why?
|
| Forms and Records Control | 1 | 2018 | 14 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 180 | 0.140 |
Why?
|
| Diagnosis-Related Groups | 1 | 2018 | 86 | 0.130 |
Why?
|
| Coronary Vasospasm | 1 | 2017 | 11 | 0.130 |
Why?
|
| Medical Records | 1 | 2018 | 140 | 0.130 |
Why?
|
| Young Adult | 3 | 2025 | 4837 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2012 | 289 | 0.130 |
Why?
|
| Rare Diseases | 1 | 2017 | 45 | 0.130 |
Why?
|
| Healthcare Disparities | 3 | 2018 | 409 | 0.130 |
Why?
|
| Program Evaluation | 4 | 2026 | 498 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2018 | 136 | 0.130 |
Why?
|
| Contracts | 1 | 2017 | 6 | 0.130 |
Why?
|
| Centralized Hospital Services | 1 | 2017 | 5 | 0.130 |
Why?
|
| Regional Health Planning | 1 | 2017 | 10 | 0.130 |
Why?
|
| beta 2-Microglobulin | 1 | 2017 | 49 | 0.130 |
Why?
|
| Negotiating | 1 | 2017 | 16 | 0.130 |
Why?
|
| Angioplasty | 2 | 2022 | 53 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.130 |
Why?
|
| Single-Domain Antibodies | 1 | 2017 | 21 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.130 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 7 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2019 | 589 | 0.130 |
Why?
|
| Self-Assessment | 1 | 2017 | 60 | 0.130 |
Why?
|
| Skin | 1 | 2020 | 428 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 555 | 0.120 |
Why?
|
| Hospitals, Teaching | 1 | 2017 | 105 | 0.120 |
Why?
|
| Inservice Training | 1 | 2017 | 85 | 0.120 |
Why?
|
| Education, Medical, Continuing | 1 | 2017 | 92 | 0.120 |
Why?
|
| Computer-Assisted Instruction | 1 | 2017 | 80 | 0.120 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 220 | 0.120 |
Why?
|
| Amyloidosis | 1 | 2017 | 70 | 0.120 |
Why?
|
| Models, Cardiovascular | 1 | 2017 | 83 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2016 | 125 | 0.120 |
Why?
|
| Recovery of Function | 2 | 2025 | 290 | 0.120 |
Why?
|
| Critical Care | 1 | 2020 | 416 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 931 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2016 | 144 | 0.110 |
Why?
|
| Practice Management, Medical | 1 | 2015 | 20 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2020 | 210 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 769 | 0.110 |
Why?
|
| Treatment Failure | 2 | 2015 | 208 | 0.100 |
Why?
|
| Turner Syndrome | 1 | 2013 | 9 | 0.100 |
Why?
|
| Neoplasm Staging | 3 | 2010 | 552 | 0.100 |
Why?
|
| Medicaid | 1 | 2017 | 375 | 0.100 |
Why?
|
| Subclavian Artery | 1 | 2013 | 26 | 0.100 |
Why?
|
| Troponin | 1 | 2013 | 39 | 0.100 |
Why?
|
| Patient Admission | 2 | 2018 | 199 | 0.100 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2010 | 12 | 0.100 |
Why?
|
| Tuberculosis, Cardiovascular | 1 | 2012 | 2 | 0.100 |
Why?
|
| Aneurysm | 1 | 2013 | 58 | 0.090 |
Why?
|
| Cryopreservation | 1 | 2012 | 30 | 0.090 |
Why?
|
| Mycobacterium bovis | 1 | 2012 | 29 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 372 | 0.090 |
Why?
|
| BCG Vaccine | 1 | 2012 | 57 | 0.090 |
Why?
|
| Hypertension | 1 | 2017 | 616 | 0.090 |
Why?
|
| Bioprosthesis | 1 | 2012 | 38 | 0.090 |
Why?
|
| Critical Illness | 2 | 2018 | 339 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2025 | 2162 | 0.090 |
Why?
|
| Adult | 5 | 2025 | 17461 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 272 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 109 | 0.090 |
Why?
|
| Colectomy | 2 | 2009 | 123 | 0.080 |
Why?
|
| Linear Models | 1 | 2012 | 405 | 0.080 |
Why?
|
| Neuroectodermal Tumors | 1 | 2010 | 2 | 0.080 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2010 | 14 | 0.080 |
Why?
|
| Carotid Artery Diseases | 1 | 2010 | 61 | 0.080 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2010 | 10 | 0.080 |
Why?
|
| Sarcoma | 1 | 2010 | 36 | 0.080 |
Why?
|
| Health Resources | 1 | 2010 | 92 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 92 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2009 | 130 | 0.080 |
Why?
|
| Diverticulitis | 1 | 2009 | 38 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 102 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2009 | 96 | 0.070 |
Why?
|
| Social Class | 1 | 2009 | 137 | 0.070 |
Why?
|
| Specialties, Surgical | 1 | 2008 | 46 | 0.070 |
Why?
|
| Organ Transplantation | 1 | 2008 | 46 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 377 | 0.070 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2008 | 90 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 642 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 318 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2008 | 157 | 0.060 |
Why?
|
| Workflow | 1 | 2026 | 77 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2009 | 445 | 0.060 |
Why?
|
| Age Factors | 4 | 2010 | 1592 | 0.060 |
Why?
|
| Aorta, Thoracic | 1 | 2025 | 80 | 0.060 |
Why?
|
| Amputees | 1 | 2025 | 3 | 0.060 |
Why?
|
| Artificial Limbs | 1 | 2025 | 6 | 0.060 |
Why?
|
| ROC Curve | 2 | 2020 | 292 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2009 | 492 | 0.050 |
Why?
|
| Algorithms | 2 | 2026 | 1050 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2024 | 102 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2024 | 85 | 0.050 |
Why?
|
| Sex Factors | 2 | 2021 | 995 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2025 | 216 | 0.050 |
Why?
|
| Cardiovascular Agents | 1 | 2024 | 107 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2018 | 288 | 0.050 |
Why?
|
| Aspirin | 1 | 2024 | 172 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 463 | 0.050 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2022 | 43 | 0.050 |
Why?
|
| Child | 2 | 2023 | 4623 | 0.040 |
Why?
|
| Optical Fibers | 1 | 2021 | 11 | 0.040 |
Why?
|
| Committee Membership | 1 | 2021 | 8 | 0.040 |
Why?
|
| Technology | 1 | 2021 | 53 | 0.040 |
Why?
|
| Femoral Artery | 1 | 2022 | 104 | 0.040 |
Why?
|
| Catheters | 1 | 2021 | 76 | 0.040 |
Why?
|
| Paraparesis | 1 | 2021 | 9 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2021 | 77 | 0.040 |
Why?
|
| Protein Binding | 1 | 2025 | 1632 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2021 | 111 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 118 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 76 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 18 | 0.040 |
Why?
|
| Homozygote | 1 | 2020 | 122 | 0.040 |
Why?
|
| Phosphatidylinositols | 1 | 2020 | 51 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 265 | 0.040 |
Why?
|
| Glycosylation | 1 | 2020 | 139 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 87 | 0.040 |
Why?
|
| Pedigree | 1 | 2020 | 193 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1451 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2019 | 74 | 0.040 |
Why?
|
| Catheterization, Central Venous | 1 | 2020 | 84 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 106 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2019 | 116 | 0.040 |
Why?
|
| Mice | 2 | 2025 | 11138 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2010 | 578 | 0.040 |
Why?
|
| Propensity Score | 2 | 2010 | 192 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 216 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 371 | 0.040 |
Why?
|
| Animals | 3 | 2025 | 21381 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 590 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 441 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 3488 | 0.030 |
Why?
|
| Certification | 1 | 2018 | 59 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 180 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 110 | 0.030 |
Why?
|
| Competitive Bidding | 1 | 2017 | 4 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2017 | 41 | 0.030 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2017 | 20 | 0.030 |
Why?
|
| Hospital Charges | 1 | 2017 | 23 | 0.030 |
Why?
|
| Protein Aggregates | 1 | 2017 | 24 | 0.030 |
Why?
|
| Doxycycline | 1 | 2017 | 47 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 1588 | 0.030 |
Why?
|
| Learning Curve | 1 | 2017 | 33 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 281 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2017 | 293 | 0.030 |
Why?
|
| Cadaver | 1 | 2017 | 134 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2017 | 130 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2018 | 224 | 0.030 |
Why?
|
| Shock | 1 | 2016 | 33 | 0.030 |
Why?
|
| North America | 1 | 2016 | 114 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 279 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2009 | 1143 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 149 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 300 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2017 | 214 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 447 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2015 | 67 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 682 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 1659 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2015 | 64 | 0.030 |
Why?
|
| Health Care Sector | 1 | 2015 | 20 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 36 | 0.030 |
Why?
|
| Angiography | 1 | 2015 | 154 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 326 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 373 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2015 | 59 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2015 | 93 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 106 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 308 | 0.030 |
Why?
|
| Emergencies | 1 | 2014 | 124 | 0.030 |
Why?
|
| Program Development | 1 | 2015 | 208 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 2633 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 37 | 0.020 |
Why?
|
| Carotid Artery, Common | 1 | 2013 | 30 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 230 | 0.020 |
Why?
|
| Administration, Intravesical | 1 | 2012 | 14 | 0.020 |
Why?
|
| Curriculum | 1 | 2017 | 610 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 1567 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 628 | 0.020 |
Why?
|
| Skilled Nursing Facilities | 1 | 2010 | 80 | 0.020 |
Why?
|
| Home Care Services | 1 | 2010 | 104 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 2009 | 23 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2009 | 58 | 0.020 |
Why?
|
| Specialization | 1 | 2009 | 82 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2776 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2009 | 70 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2009 | 97 | 0.020 |
Why?
|
| Health Services Research | 1 | 2009 | 265 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 170 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 237 | 0.020 |
Why?
|
| Acute Disease | 1 | 2009 | 663 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 606 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 804 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2009 | 326 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 599 | 0.010 |
Why?
|